Dermatology

The AJMC® Dermatology compendium is a comprehensive resource for clinical news and expert insights for diseases related to the skin, hair, and nails.

Latest News

Alopecia areata. | Image Credit: cattyphoto - stock.adobe.com
Study Highlights Unmet Needs in Measuring Patient Experiences in Alopecia Areata

April 29th 2025

Significant unmet needs were found among high-quality validation studies on the internal structure of patient-reported outcome measures (PROMs) specific to alopecia areata (AA), a common hair loss condition with substantial quality of life impacts.

Chronic hand eczema. | Image Credit: IIIRusya - stock.adobe.com
Chronic Hand Eczema Has Significant Impacts on Patients' Lives, Survey Reveals

April 22nd 2025

Raj Chovatiya, MD, PhD, MSCI
Addressing Unmet Needs, Emerging Treatment for Atopic Dermatitis: Raj Chovatiya, MD, PhD

April 9th 2025

Migrant Populations. | Image Credit: wladimir1804 - stock.adobe.com
Review Explores Skin Health Risks of US Migrant Populations

April 9th 2025

Research presented. | Image Credit: somneuk - stock.adobe.com
Managing Skin Conditions: Highlighting Ruxolitinib Cream, Phototherapy Efficacy and Cost

April 8th 2025

Topical Therapies for the Treatment of Atopic Dermatitis: Balancing Safety, Efficacy, and Access

Develop a deeper understanding of the atopic dermatitis (AD) patient journey, explore topical therapies and treatment sequencing advancements, and gain insight regarding the payer’s perspective on AD therapies.

Atopic Dermatitis Payer Perspectives
Continuing Medical Education
View All
May 1st 2025

Treatment Gaps in the Management of Generalized Pustular Psoriasis: Enhancing the Role of Managed Care

1.5 Credits / Dermatology, Immunology
May 1st 2025

Advancing Patient Outcomes in Hidradenitis Suppurativa: Updates and Strategies for Managed Care

1.5 Credits / Dermatology

More News

Melinda Gooderham, MD, MSc, FRCPC, Peterborough Regional Health Centre
May 18th 2023

Dr Melinda Gooderham Discusses Studies on Emerging Therapies for Atopic Dermatitis

Pearl Steinzor
Melinda Gooderham, MD, MSc, FRCPC, Peterborough Regional Health Centre in Ontario, Canada, discusses recent trials and studies that have been conducted on emerging therapies for patients with atopic dermatitis.
woman checking her skin for an abnormal mole for signs of melanoma skin cancer: © MW Photography - stock.adobe.com
May 16th 2023

Improvement Needed in Study Interventions to Better Skin Self-examination Adherence

Jaime Rosenberg
The study, using an adaption of the World Health Organization framework for adherence, characterized strategies built into the design, conduct, and reporting of melanoma trials, offering insights into potential improvements for skin self-examination in research.
Pimples on the belly of a pregnant woman,, home living room: © Андрей Журавлев - stock.adobe.com
May 7th 2023

Research Points to Inconsistencies in Acne Treatment for Pregnant Women

Gianna Melillo
Common treatments for acne are known to be unsafe for pregnant women, but alternative treatments exist that are safe for use; however, actual treatment patterns within this patient population are unclear.
Hands with different skin tones raised
May 2nd 2023

Disparities in AD Treatment: What Can Be Done?

Julia Bonavitacola
Reducing disparities in the treatment of atopic dermatitis (AD) was the focus of a session of the final day of the Revolutionizing Atopic Dermatitis 2023 conference.
Andy Blauvelt, MD, MBA, president, Oregon Medical Research Center
May 2nd 2023

Dr Andy Blauvelt on Selecting the Right Patient for Systemic Therapy or Biologics to Treat AD

Pearl Steinzor
Andy Blauvelt, MD, MBA, president of Oregon Medical Research Center, discusses the use of systemic therapies vs biologics and why adherence is so important when treating patients with atopic dermatitis (AD).
Larry Eichenfield, MD, professor of dermatology and pediatrics, vice chair, Department of Dermatology at the University of California San Diego (UCSD) School of Medicine, and chief of pediatric and adolescent dermatology, Rady Children's Hospital San Diego
May 2nd 2023

Dr Larry Eichenfield: A Changing Therapy Landscape Provides More Options for Infants With AD

Pearl Steinzor
Larry Eichenfield, MD, professor of dermatology and pediatrics and vice chair of the Department of Dermatology at the University of California San Diego School of Medicine and chief of pediatric and adolescent dermatology at Rady Children's Hospital San Diego, discusses the use of different treatments and biologics for atopic dermatitis (AD) in infants, which he presented at the Revolutionizing Atopic Dermatitis conference.
Man scratching rash
May 1st 2023

Panel Focuses on Burgeoning Therapies in Atopic Dermatitis

Julia Bonavitacola
A panel held at Revolutionizing Atopic Dermatitis 2023 reviewed therapies to expect within the next year for the treatment of atopic dermatitis (AD) as well as investigational therapies currently undergoing trials.
Melinda Gooderham, MSC, MD, FRCPC, dermatologist and clinical researcher, Peterborough Regional Health Centre
May 1st 2023

Dr Melinda Gooderham Discusses Emerging Therapies in Atopic Dermatitis

Pearl Steinzor
Melinda Gooderham, MSc, MD, FRCPC, dermatologist and clinical researcher at Peterborough Regional Health Centre, discusses emerging topical and biologic therapies expected to be available later this year.
Robert Sidbury, MD, MPH, Seattle Children's Hospital
May 1st 2023

Dr Robert Sidbury: How to Treat Facial Atopic Dermatitis in Infants

Pearl Steinzor
Robert Sidbury, MD, MPH, professor of pediatrics at Seattle Children's Hospital, discusses treatment approaches for atopic dermatitis of the face in infancy, which he presented at the Revolutionizing Atopic Dermatitis conference.
Doctor looking at rash
May 1st 2023

Symposium Highlights New Research on JAK, PDE-4 Inhibitors

Julia Bonavitacola
Janus kinase (JAK) and phosphodiesterase-4 (PDE-4) inhibitors were primary topics covered at the third symposium at the Revolutionizing Atopic Dermatitis fifth annual conference.
Posters Show Ruxolitinib Cream to Be Both Effective and Safe for Treating AD
April 30th 2023

Posters Show Ruxolitinib Cream to Be Both Effective and Safe for Treating AD

Julia Bonavitacola
In posters presented at the Revolutionizing Atopic Dermatitis conference, ruxolitinib cream was found to be both safe and effective in treating atopic dermatitis (AD).
Jonathan Silverberg, MD, PhD, MPH, professor of dermatology, director of Clinical Research and patch testing at the George Washington University School of Medicine and Health Sciences
April 26th 2023

Dr Jonathan Silverberg Previews the Revolutionizing Atopic Dermatitis Meeting

Pearl Steinzor
Jonathan Silverberg, MD, PhD, MPH, professor of dermatology and director of clinical research and patch testing at the George Washington University School of Medicine and Health Sciences, and chair of the Revolutionizing Atopic Dermatitis (RAD) conference, discusses some of the symposia and events at this year's conference that he is looking forward to the most.
image of a toddler
April 26th 2023

Early Trial Finds Ruxolitinib Cream Safe, Effective Among Children With AD

Gianna Melillo
In this phase 1 trial, researchers sought to investigate whether ruxolitinib cream is safe and tolerable in children aged 2 to 17 with atopic dermatitis (AD).
Doctor at computer
April 26th 2023

Revolutionizing Atopic Dermatitis Conference Promises New Ways to Learn About AD

Julia Bonavitacola
The Revolutionizing Atopic Dermatitis conference, set to begin on April 29 in Washington, DC, promises to offer symposia on emerging therapies and new insights into treating atopic dermatitis (AD).
Asian woman has acne problems on her face: © boyloso - stock.adobe.com
April 25th 2023

Review Highlights Toll of Acne Scars on Patients’ Quality of Life

Gianna Melillo
A new literature review underscores how acne is separate from acne vulgaris and requires a comprehensive clinical approach unique from those for active acne.
Acne skin: © Ocskay Bence - stock.adobe.com
April 22nd 2023

Controlling Mast Cell Activation May Help Prevent Scarring in Severe Acne

Gianna Melillo
Although many topical or systemic antibiotics exist to treat acne vulgaris, the common inflammatory skin disease is not fully treatable.
a doctor's prescription: © goodmanphoto - stock.adobe.com
April 19th 2023

Study Details Historical Changes in Medication Prescription Patterns for Atopic Dermatitis

Gianna Melillo
New study data show that prescription patterns differed depending on the type of institution they were prescribed in and the specialty of prescribing physicians.
Image of a baby with eczema: © AnastazjaSoroka - stock.adobe.com
April 14th 2023

Vitamin D Supplements During Pregnancy May Reduce Eczema in Infants

Carrie Nagorka
The study also found lasting benefits of the supplement for bone density up to age 4.
Screenshot of John Harris, MD, PhD, smiling in a Zoom video interview
April 11th 2023

Dr John Harris Discusses New Information Learned in Extension Studies for Ruxolitinib Cream

Laura Joszt, MA
Each trial extension has added new and more data and a better understanding of how ruxolitinib cream treats vitiligo in the long term, explained John Harris, MD, PhD, FAAD, director of the Vitiligo Clinic and Research Center at UMass Chan Medical School.
image of person scratching skin
April 6th 2023

What You May Have Missed at the AAD 2023 Annual Meeting

AJMC Staff
The American Academy of Dermatology (AAD) 2023 Annual Meeting took place last month in New Orleans, Louisiana, and The American Journal of Managed Care® was there to cover the latest news—catch up on what you may have missed.
woman scratching arm with atopic dermatitis irritation
March 24th 2023

Ruxolitinib Cream Has Lower Number Needed to Treat for AD Compared With Other Therapies

Laura Joszt, MA
The lower number needed to treat suggests that ruxolitinib cream may be more effective for patients with atopic dermatitis (AD), according to a poster presented at AMCP 2023.
Top 5 Most-Read Dermatology Content of 2022
December 30th 2022

Top 5 Most-Read Dermatology Content of 2022

Matthew Gavidia
This year’s most-read articles on dermatology covered the first and only FDA-approved treatment for repigmentation in patients with vitiligo, as well as other therapies for the treatment of acne, hidradenitis suppurativa, and more.
Older Black patient in hospital.
December 20th 2022

Examining Clinical Characteristics of Hidradenitis Suppurativa in Older Adults

Matthew Gavidia
A research letter examined the clinical presentation, disease severity, associated comorbidities, and management of hidradenitis suppurativa in older adults aged 65 years or older.
Health care tech.
December 17th 2022

ICYMI: Highlights From the 2022 American Academy of Dermatology Meeting

Matthew Gavidia
This American Academy of Dermatology (AAD) Annual Meeting covered a breakthrough therapy for the management of vitiligo, clinical and epidemiological differences of certain dermatologic diseases, and the role of dietary triggers on patient outcomes.
Black patient.
December 13th 2022

Racial Disparities Shown for Delayed Diagnosis, Dermatologic Care in Hidradenitis Suppurativa

Matthew Gavidia
Non-White patients with hidradenitis suppurativa reported longer delay in diagnosis than their White counterparts. In addition, Black patients did not receive dermatologic care as early in their disease course as other racial groups.
Jason Ezra Hawkes, MD.
December 10th 2022

Dr Jason Ezra Hawkes: Exciting Innovations Shown for Precision Medicine, Research, and Technology in Dermatology

Matthew Gavidia
Jason Ezra Hawkes, MD, MS, FAAD, board-certified dermatologist and associate professor of Dermatology at the University of California Davis in Sacramento, spoke on the advancement in precision medicine within dermatology and what role genetics, research, and immunology can have for care management going forward.
Physician and patient.
December 8th 2022

Lower Risk of Cardiovascular, Metabolic Outcomes Associated With Rituximab for Pemphigus Treatment

Matthew Gavidia
Patients with pemphigus reported lower risk of myocardial infarction and stroke, among other cardiovascular and metabolic outcomes, when treated with rituximab compared with the first-line corticosteroid-sparing agents azathioprine and mycophenolate mofetil.
Diversity.
December 2nd 2022

Low Diversity Shown Among Medical Students Pursuing Dermatology

Matthew Gavidia
Female allopathic medical students pursuing careers in dermatology were less likely than those pursuing other specialties to be from racial and ethnic groups underrepresented in medicine or be a sexual minority, with a lack of interest in underserved care and public health shown overall.
acne.
December 2nd 2022

Use of PRO Measures Lacking in Acne Vulgaris and Rosacea Clinical Trials, Study Finds

Matthew Gavidia
Patient-reported outcome (PRO) measures were included in approximately one-half of acne vulgaris and rosacea randomized controlled trials, despite their utility in capturing the patient perspective.
acne on a person's jawline
November 28th 2022

Different Factors Impact Quality of Life for Adults and Adolescents With Acne

Justina Petrullo
Researchers found that different factors can negatively impact the Dermatology Life Quality Index scores for adults and adolescents with acne.
<12345678910>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo